X0306 4 2013-07-26 0 0000885590 Valeant Pharmaceuticals International, Inc. VRX 0001502213 Chai-Onn Robert Roswell 2150 ST. ELZEAR BLVD. WEST LAVAL A8 H7L 4A8 QUEBEC, CANADA 0 1 0 0 EVP, Gen. Couns. & Corp. Sec. Common Stock, no par values 2013-07-26 4 M 0 19401 0 A 193448 D Common Stock, no par values 2013-07-26 4 F 0 10203 0 D 183245 D Restricted Share Units 2013-07-26 4 M 0 19401 0 D Common Stock 19401 58204 D This represents the number of units vested on the performance-based RSUs ("PSUs") that were previously reported on the original Form 4. The initial grant was reported to vest based on total shareholder return (TSR) between a price of $26.51 starting on September 28, 2010 and the average stock price for the 20 trading days starting on each measurement dates: 25% on June 28, 2013, 50% on September 28, 2013 and 25% on December 28, 2013. Unit vesting is contingent on TSR performance between 15% and 45% into between one and three shares of common stock, respectively, with early vesting possible at higher TSR levels. The PSUs have already paid out for the first two of the three potential shares of common stock. This number represents common shares purchased by the officer, common shares received upon settlement and/or exercise of previously granted equity awards, as well as other outstanding equity awards that were previously reported in Table 1. This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of Performance Share Units. by: Nicholas Zanoni for Robert Chai-Onn 2013-07-30